Dr. Tishler is a Cannabis Specialist. Through his training in Internal Medicine and years of practice as an Emergency Physician, Dr. Tishler brings his knowledge, reason, and caring to patients here at inhaleMD, and through his advocacy work at the local and national levels.
Dr. Tishler graduated from both Harvard College and Harvard Medical School, trained at the Brigham and Women’s Hospital, and is faculty at both the Brigham and Women’s Hospital and Harvard Medical School. He has spent many years working with the underserved, particularly providing care for Veterans. Having treated countless patients harmed by alcohol and drugs, his observation that he had never seen a cannabis overdose lead Dr. Tishler to delve deeply into the science of cannabis safety and treatment.
Dr. Tishler is also a parallel entrepreneur working for patients’ wellbeing in the corporate space, helping to elevate dosing and safety profiles of medication, and helping to establish best practice for bringing new Cannabis products to market.
Dr. Tishler is a frequent speaker and author on a variety of topics related to the medical applications of cannabis. He is the President of the Association of Cannabis Specialists which aims to educate clinicians, lawmakers, and the industry about best practices and needed tools for proper patient care.
Stacia Woodcock is a Doctor of Pharmacy and currently serves as the Assistant Director of Dispensary Operations and Practitioner Outreach Liaison for Curaleaf New York, a registered medical cannabis dispensary company. She became a dedicated cannabis clinician after seeing first-hand the ability of medical cannabis to reduce the polypharmacy rampant in today’s society and significantly improve patient outcomes with minimal side effects. She has been a featured medical expert on The Dr. Oz Show and The Rachael Ray Show, among others, and is devoted to being an advocate for patients and caregivers in the medical cannabis space.
Elizabeth G. Dost, RN, is a senior health care executive with more than 25 years-experience in the Boston market. She currently is a Senior Executive Healthcare Consultant in Medical Cannabis and has done so since 2012, making her the first nurse in Massachusetts to publicly advocate for the Humanitarian Use of Medical Marijuana.
Ms. Dost has donated lecture time to the Hospice and Palliative Care Federation of Massachusetts, having presented in 2017 and 2018 on “Cannabis and Hospice”. Ms. Dost has participated on panels at NECANN in Boston two years, lectured for Patients Out of Time on HIPAA and Cannabis; and at Dartmouth Hitchcock Parkinson’s Conference on Cannabis and Parkinson’s Disease. She presented a full year on cannabis, the ECS and patient/nurse implications for the Massachusetts Nurses Association. Additionally, Beth appears in the seven-episode docuseries, “The Sacred Plant”. She has been a featured guest on national radio.
Beth is proud to serve as Clinical Director for the Massachusetts Patient’s Advocacy Alliance (MPAA) and has done so since 2014. Beth participated in public policy creation. She has testified on cannabis before the State of Massachusetts’ Department of Public Health, the Senate and House of Representatives of Massachusetts, to state representatives and senators, and via invitation to the Cannabis Control Commission both in public forum and by personal appointment.
Most notably, Elizabeth G. Dost RN, was awarded Ernst and Young, Entrepreneur of the Year in Healthcare, New England Region and is a member of their elite Alumni group.
Dr. Julia Arnsten is Chief of the Division of General Internal Medicine and a Professor of Medicine, Psychiatry & Behavioral Sciences, and Epidemiology & Population Health. Dr. Arnsten is a general internist with a long-standing interest in behavioral medicine, including adherence with medication-taking, nicotine dependence, and substance abuse. She currently leads led an NIH-funded research program focused on addiction and chronic medical illness.
Dr. Arnsten graduated from the New York University School of Medicine in 1990 and completed residency training in Primary Care Internal Medicine at Bellevue Hospital and New York University Medical Center in 1993. She then completed a research fellowship in General Internal Medicine at Harvard Medical School and Massachusetts General Hospital. From 1998-2002, Dr. Arnsten was a Robert Wood Johnson Generalist Physician Faculty Scholar. In 2002, she was awarded an R25 grant from NIDA to start a clinical addiction research and education fellowship for physicians; this program has now been funded for over a decade. Dr. Arnsten has been recognized for outstanding teaching and mentoring with several local and national awards.
Dr. Sandra Carrillo is a Specialist in Cannabinoids Based Medicine. She is President of the Colombian Medical Association of Cannabis Medicine (ASOMEDCCAM) and Professor in charge of the Scientific Program of Medicinal Cannabis Faculty of Medicine University of Panama.
Dr. Carrillo is Co-Founder Medicann IPS Medical Cannabis Clinics (Colombia) and in addition to these responsibilities she is a review board member for the American Journal of Endocannabinoid Medicine (AJEM) and a Scientific Committee Member of the Columbian Medicinal Cannabis Observatory (OCCM).
Dr. Carrillos holds a Masters in Health Services Management, and certified in Antiaging and Regenerative medicine. She is also a former professor for the first certification of applications of Cannabinoids in Clinical practice for medical doctors at CES University.
She is an International speaker and advocate with appearances on different continents including USA, Mexico, Colombia, Panama, Jamaica, Brazil, Portugal, Malta, and the United Kingdom.
Her trainings and certifications include: Society of Cannabis Clinicians( TMC iGlobal) ,Diplomate Certification Program for Clinicians in Cannabinoids Prescription CES University, Certified in Medical Cannabis program Oaxterdam California ,Spectrum Academy Certification (Ottawa), AJEM University Certification in Cannabinoids Based Medicine and Pharmacology University Puerto Rico.
She continues her work on educational program to train Doctors and Health Care Practitioners and developing Research protocols.
Sandra is the Co-Founder of the Panama Food Bank and Volunteer at the Children´s Epilepsy foundation (LUCES) in Panama.
Dr. Jahan Marcu has over 15 years of experience in cannabinoid research, policy, and operations. He has been a passionate advocate focused on consumer safety and the medical benefits of cannabis. He is also among a select group of professionals globally that has earned a PhD focused on the endocannabinoid system (with research on the structure and function of cannabinoid receptors, molecular pharmacology of the endocannabinoid system, and the role of the ECS in bone).
Dr. Marcu’s work has been instrumental to facilitating and supporting fact-based, scientific approaches vital to industry and patients. This has included research focused on solving the structure and function of cannabinoid receptors, the anti-cancer properties of cannabis compounds, as well as method development and validation for analyzing complex formulations. Furthermore, his efforts include the development of international certification and training programs, co-authoring American Herbal Pharmacopeia’s Cannabis Quality Control and Therapeutic Monographs, and assisting in the creation of the first standards for industry as a committee chairman of the cannabis committee for the American Herbal Products Association (AHPA). His dedication to consumer safety is further evident in his work to co-develop a biotech application to predict drug-drug interactions between cannabis and commonly prescribed pharmaceutical drugs. Additionally, Dr. Marcu published one of the first product safety study on CBD products.
He is presently the Editor-In-Chief of the American Journal of Endocannabinoid Medicine. He is the co-founder and former Chief Science Officer for the International Research Center on Cannabis and Health (aka Institute of Cannabis Research). He is also founder and past-chair of the Cannabis Chemistry Sub-division of the American Chemical Society, the world’s largest and oldest professional scientific society. Further illustrating the recognition earned through his efforts, he has been asked to serve on multiple expert government advisory and trade association committees, as well as scientific organizations including ASTM (D37 Subcommittee chair), AHPA Cannabis committee (past-chair), ACS Cannabis Chemistry Subdivision (CANN), AOCS, AOAC, IACM(past BOD), and IMCPC (co-founder).
Elizabeth (Lisa) Whittemore’s work at HMA focuses on strategic planning, practice transformation, behavioral health integration, alternative payment models, and delivery system reform. An executive with over thirty years of experience in a variety of healthcare settings, Lisa brings her training as a clinical social worker and knowledge of the challenges of delivering care to her work. During her time at HMA, Lisa wrote and was awarded a large technical assistance grant to provide technical assistance to primary care practices who are integrating behavioral health in Massachusetts. Her work has also included supporting providers and health plans to prepare for value-based care.
Projects have included assessments of practice readiness, leadership development, trainings to implement team-based care, developing and implementing models of care management, and implementing the collaborative care model.
Prior to joining HMA, Lisa worked for Blue Cross Blue Shield of Massachusetts as Vice President of Network Performance Improvement; in this role, she was responsible for working with providers who were participating in a full risk payment model, the Alternative Quality Contract. Lisa has held leadership roles in community health centers, community hospitals, academic medical centers, community mental health centers, and agencies on aging. Lisa is experienced in helping practices transform to team based care and to integrate behavioral health clinicians into primary care practice settings. Since joining HMA, Lisa has worked with several primary care associations and their member organizations to prepare them for new payment models.
David (Dedi) Meiri, PhD, is an Assistant Professor at the Faculty of Biology at the Technion Israel Institute of Technology and a member of the Technion Integrated Cancer Center (TICC). Dr. Meiri’s scientific background is highly diverse. He holds a M.Sc. in biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. Dr. Meiri conducted his post-doctoral fellowship at the Ontario Cancer Institute where he focused on the role of the GEF-H1 protein in tumor invasion and metastasis. During his post-doctoral studies, he expanded his knowledge in human biology and cancer pathogenesis and succeeded within a very short time frame to receive worldwide recognition as an expert in the fields of G-protein coupled receptors (GPCRs) and small GTPases. Upon completion of his post-doctoral fellowship, Dr. Meiri took a position at the Technion Israel Institute of Technology, where he heads the “Laboratory of Cancer Biology and Cannabinoid Research”.
Presently, his lab investigates the therapeutic potential of phytocannabinoids, the unique active compounds of the Cannabis sativa plant. On top of other research being conducted in the lab, the main focus of his research is to determine the antitumor effects of cannabinoids, including the anti-metastatic and pro-apoptotic effects of phytocannabinoids.
In addition to the laboratory cannabis research performed on-site, Dr. Meiri collaborates with cannabis growers, clinicians, major manufacturers and distributors of medical cannabis for the purpose of revolutionizing cannabis treatment. He is operating the “Cannabis Database Project” and his lab is currently involved in eight clinical trials covering diverse aspects of cannabis treatment such as colon disease, pain prevention, cancer treatment and epilepsy.
Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees which seek to advance the fundamental understanding of optimal cannabis usage and minimization of adverse side effects.